{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:07:40Z","timestamp":1789672060284,"version":"4.0.1"},"reference-count":9,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The COVID-19 pandemic has highlighted racial health disparities within the United States. Although social determinants of health are the most likely drivers of this disparity, it is possible that genetic traits enriched in the black population like sickle cell trait (SCT) could worsen the morbidity and mortality of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients admitted for SARS-CoV-2 infection who identified as black or African American were included in the study (n = 166). Blood remnants were tested for SCT, and clinical data were abstracted from the chart. There was no difference in mortality between those with SCT and those without. There was no difference in respiratory complications between groups, but those without SCT had a much higher burden of chronic lung disease (P = .004). Those with SCT had higher creatinine on admission (P = .004), but no difference in in-hospital renal complications (P = .532). Notably, 12% of the cohort had SCT, which is higher than the expected 7.31% (P = .025). Our study did not show any evidence of increased end organ damage, morbidity, or mortality from SARS-CoV-2 infection among patients with SCT but did show differences in admission creatinine and preexisting lung disease.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004977","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T19:22:45Z","timestamp":1632856965000},"page":"3690-3693","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection"],"prefix":"10.1182","volume":"5","author":[{"given":"Lauren E.","family":"Merz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Mistry","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revital","family":"Freedman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Menard","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Dorfman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Soo","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Jolley","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen O.","family":"Achebe","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, and"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"issue":"19","key":"2021092815394479400_B1","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2020.6548","article-title":"COVID-19 and African Americans","volume":"323","author":"Yancy","year":"2020","journal-title":"JAMA."},{"issue":"24","key":"2021092815394479400_B2","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2020.8598","article-title":"COVID-19 and racial\/ethnic disparities","volume":"323","author":"Webb Hooper","year":"2020","journal-title":"JAMA."},{"issue":"1","key":"2021092815394479400_B3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bjh.13363","article-title":"Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory","volume":"170","author":"Key","year":"2015","journal-title":"Br J Haematol."},{"issue":"5","key":"2021092815394479400_B4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1516257","article-title":"Sickle cell trait, rhabdomyolysis, and mortality among U.S. Army soldiers","volume":"375","author":"Nelson","year":"2016","journal-title":"N Engl J Med."},{"issue":"1","key":"2021092815394479400_B5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40798-018-0131-6","article-title":"Sickle cell trait and sudden death","volume":"4","author":"Mitchell","year":"2018","journal-title":"Sports Med Open."},{"issue":"49","key":"2021092815394479400_B6","first-page":"1155","article-title":"Incidence of sickle cell trait--United States, 2010","volume":"63","author":"O","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"7","key":"2021092815394479400_B7","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/bloodadvances.2020003741","article-title":"COVID-19 in individuals with sickle cell disease\/trait compared with other Black individuals","volume":"5","author":"Singh","year":"2021","journal-title":"Blood Adv."},{"issue":"3","key":"2021092815394479400_B8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2215\/CJN.06960520","article-title":"Acute kidney injury among black patients with sickle cell trait and sickle cell disease","volume":"16","author":"Olaniran","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"18","key":"2021092815394479400_B9","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2016-01-694422","article-title":"Elevated D-dimer levels in African Americans with sickle cell trait","volume":"127","author":"Naik","year":"2016","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3690\/1823601\/advancesadv2021004977.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3690\/1823601\/advancesadv2021004977.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T19:22:55Z","timestamp":1632856975000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/18\/3690\/476987\/Impact-of-sickle-cell-trait-on-morbidity-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":9,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,9,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004977","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}